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Background: HIV-1 formation is driven by the viral structural polyprotein Gag, which assembles at the plasma
membrane into a hexagonal lattice. The C-terminal p6Gag domain harbors short peptide motifs, called late domains,
which recruit the cellular endosomal sorting complex required for transport and promote HIV-1 abscission from
the plasma membrane. Similar to late domain containing proteins of other viruses, HIV-1 p6 is phosphorylated at
multiple residues, including a highly conserved serine at position 40. Previously published studies showed that an
S40F exchange in p6Gag severely affected virus infectivity, while we had reported that mutation of all phosphorylatable
residues in p6Gag had only minor effects.
Findings: We introduced mutations into p6Gag without affecting the overlapping pol reading frame by using an
HIV-1 derivative where gag and pol are genetically uncoupled. HIV-1 derivatives with a conservative S40N or a
non-conservative S40F exchange were produced. The S40F substitution severely affected virus maturation and
infectivity as reported before, while the S40N exchange caused no functional defects and the variant was fully
infectious in T-cell lines and primary T-cells.
Conclusions: An HIV-1 variant carrying a conservative S40N exchange in p6Gag is fully functional in tissue culture
demonstrating that neither S40 nor its phosphorylation are required for HIV-1 release and maturation. The
phenotype of the S40F mutation appears to be caused by the bulky hydrophobic residue introduced into a
flexible region.
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HIV-1 assembly is driven by the viral Gag polyprotein.
Gag is necessary and sufficient for particle formation, and
is composed of four functional subunits. The N-terminal
MA domain targets Gag to the plasma membrane, where
~2,500 Gag molecules form the curved, hexagonal imma-
ture lattice of HIV-1, which is stabilized by intermolecular
CA domain interactions. The NC domain is responsible
for packaging viral genomic RNA [1]. Crucial motifs
for particle release lie within the 52 amino acids long
C-terminal p6Gag domain. This domain harbors so-called
late domains, which recruit the cellular endosomal sorting
complex required for transport (ESCRT) promoting ab-
scission of progeny particles from the host cell. Other mo-
tifs in p6Gag mediate incorporation of the viral accessory
protein Vpr into HIV-1 particles [2-4]. During maturation,* Correspondence: Hans-Georg.Kraeusslich@med.uni-heidelberg.de
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reproduction in any medium, provided the orimmature HIV-1 gains infectivity following proteolytic
cleavage of Gag into its functional domains by the viral
protease [1].
p6Gag has been shown to be the predominant phospho-
protein in HIV-1 particles [5]. It is phosphorylated at sev-
eral positions, including the highly conserved residue S40
[5-8]. S40 phosphorylation has been detected in infected
cells and viral particles [7], and this residue can be phos-
phorylated by atypical protein kinase C (aPKC) in vitro [6].
To determine the role of p6 phosphorylation for HIV-1
replication, we had recently performed a comprehensive
mutational analysis of p6 [7]. The use of an HIV-1NL4-3
based proviral plasmid with genetically uncoupled gag and
pol open reading frames (ORFs) (pNL4-3unc) allowed us to
freely introduce mutations in the p6gag encoding region
without affecting the pol ORF. In this context, we changed
all phosphorylatable residues (i.e., Ser, Thr, Tyr) within
p6Gag with exception of the essential threonine in the
PTAP late domain motif. The resulting virus, NL4-3uncFLral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Radestock et al. Retrovirology  (2014) 11:114 Page 2 of 5exhibited no significant difference in replication capacity
compared to wild-type. This result led us to conclude that
p6 phosphorylation is dispensable for viral morphogenesis
and replication in cell culture.
In contrast, previous studies had reported that an
S40F change in p6Gag impaired proteolytic maturation of
Gag, reduced viral infectivity and delayed replication in
T-cell lines [9,10]. Furthermore, enhanced membrane
binding affinity of a synthetic p6 C-terminal fragment
was observed in vitro upon substitution of Ser40 by Phe
or upon adding a phosphate group to this residue [11].
The S40F exchange was furthermore shown to result
in an enhanced interaction of Gag with the ESCRT-
associated protein Alix [9]. Taken together, these studies
suggested an important role of S40 in Gag assembly [9],
viral maturation [10], Vpr incorporation [6], and p6
membrane binding [11], in apparent contradiction to
our observation that an HIV-1 derivative carrying muta-
tions at 12 positions within p6, including S40, was fully
functional in cell culture [7].
A major difference between our work [7] and the studies
reported by others [6,9-11] was that the latter employed a
chemically drastic Ser to Phe exchange in order to main-
tain the amino acid sequence of the overlapping pol ORF,
whereas the gag-pol uncoupling strategy allowed us to se-
lect the most conservative substitution, Ser to Asn. In
order to resolve the apparent discrepancies between our
study and data published by others, we performed a direct
side-by-side comparison of viruses carrying either an Asn
or a Phe residue at position 40 of p6Gag.
The analysis included the previously described proviral
plasmids pNL4-3unc with uncoupled wild-type gag and pol
and pNL4-3uncFL, in which all phosphorylatable residues
in p6Gag except for T8, which is required for L-domain
function [12], had been changed to chemically similar,
but not phosphorylatable residues [7]. A derivative of
pNL4-3uncFL in which the substitution at position 40 of
p6Gag was reversed to the wild-type Ser-codon while
retaining all other substitutions (pNL4-3uncFL-N40S) was
also included (Figure 1A). Mutant viruses were produced
by transfection of HEK 293 T cells [13] using calcium phos-
phate and tested for efficiency of particle formation, Gag
processing, Vpr incorporation, and infectivity. Controls
included a release deficient late domain-defective variant
(NL4-3 late(-), [14]), a derivative carrying alanine substitu-
tions in the FRFG motif of p6Gag and impaired in Vpr in-
corporation (NL4-3 Vpr(-), [3]), and a derivative which does
not express Vpr (NL4-3 ΔVpr).
For assessment of virus release, culture media were
harvested 30 h post transfection (p.t.), cleared by brief
centrifugation followed by ultracentrifugation through a
20% (w/w) sucrose cushion to pellet virus particles.
Samples of cell and particle lysates were separated by
SDS-PAGE and proteins were transferred to a PVDFmembrane. HIV-1 CA-containing proteins were detected
by quantitative immunoblotting using polyclonal sheep
antiserum against recombinant CA (Figure 1B), and HIV-
1 particle release was quantified by determining the ratio
of the amount of pelletable extracellular CA-containing
proteins over the total amount of CA-containing proteins
(Figure 1C). As expected, NL4-3 late(-) showed strongly
reduced particle release compared to wild-type, accom-
panied by a characteristic increase in the proportion of
processing intermediates, in particular CA-SP1. Variants
NL4-3uncFL, FL-N40S, and S40N displayed wild-type Gag
processing and particle release. Increased amounts of the
CA-SP1 processing intermediate were observed in case of
the S40F variant, consistent with previous reports [9,10],
and particle release was also slightly higher in this case
(Figure 1B,C).
Kudoh and coworkers reported that (i) an S40A sub-
stitution in p6Gag abolished incorporation of exogenously
expressed Vpr into virus-like Gag particles (VLPs) and (ii)
a PKC inhibitor, presumed to prevent phosphorylation of
S40, impaired HIV-1 replication in primary macrophages
[6]. These authors proposed that S40 phosphorylation
may be required for Vpr incorporation into HIV-1 parti-
cles, and may thus be functionally relevant for replication
in non-dividing cells, where the accessory protein Vpr is
required [16]. In our previous analyses, we had not ob-
served a block of Vpr incorporation in the case of pNL4-
3uncFL, where all phosphorylatable residues including S40
had been mutated [7]. This was confirmed in the present
study, using a polyclonal rabbit antiserum raised against
synthetic HIV-1 Vpr. Our analysis further revealed that
neither the S40F nor the S40N exchange altered Vpr
incorporation into HIV-1 (Figure 2). We conclude that the
Vpr incorporation block reported before [6] is either a
specific property of the S40A variant, or, more likely, rep-
resents a feature of the Gag/Vpr overexpression system
used in the prior study that is not observed in the native
viral context.
Single round infectivity of wild-type and mutant virus
preparations was assessed by titration on HeLa TZM-bl in-
dicator cells [17] (Figure 3A). Viral titers were determined
by endpoint titration on C8166 T-cells [18] (Figure 3B).
Neither single-round infectivity nor viral titer of the vari-
ants HIV-1NL4-3uncFL, FL-N40S, or S40N, respectively, dif-
fered significantly from that of wild-type HIV-1NL4-3unc
(Figure 3A,B). In line with published results [9,10], infectiv-
ity was severely decreased for the S40F variant with a simi-
lar reduction as observed for the release deficient late(-)
control.
Finally, we investigated the replication kinetics of the
mutant HIV-1 panel in primary human peripheral blood
mononuclear cells (PBMC) (Figure 4). PBMC obtained
from three healthy blood donors were mixed, activated

















































































Figure 2 Vpr incorporation into HIV-1 particles. (A) Immunoblot analysis of Vpr incorporation. Virions were collected from culture media of HEK
293 T cells transfected with the respective proviral plasmids by ultracentrifugation through a sucrose cushion. NL4-3 Vpr(−) (generated by transferring a
SpeI – AgeI fragment from pNL43_E-_R-_Luc3/p6:M1A ([3]) into pNL4-3) and NL4-3 ΔVpr were used as negative controls. Samples were separated by
SDS-PAGE, and viral particles were analyzed by quantitative immunoblot (LiCor) using antisera against recombinant HIV-1 CA (top) and Vpr (bottom).
The positions of molecular mass standards are shown on the left and proteins are indicated on the right. (B) Quantification of Vpr incorporation. The
ratio of Vpr to CA represents relative signal intensities from quantitative immunoblots, as shown in panel A. Mean values and SD from three independent
experiments performed in duplicates are shown. p-values were calculated using an unpaired student’s t-test (n.s. > 0.05, *** < 0.001).
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Figure 1 HIV-1 p6Gag variants and their effect on Gag processing and viral release. (A) Scheme of the gag and pol ORFs in the HIV-1NL4-3unc
genome [15]. The arrow with an asterisk indicates the frameshift signal at the 3’ end of gag. Amino acid sequences of the altered p6 sequences of the
NL4-3unc variants are shown below; mutated residues are indicated. The NL4-3 late(-) and Vpr(-) variants were constructed in the wild-type pNL4-3
proviral plasmid with overlapping gag and pol reading frames. (B) Gag processing and particle release efficiency. Virus particles were prepared by
ultracentrifugation from the culture media of HEK 293 T cells transfected with the indicated proviral plasmids. Cell lysates (top panel) and virus particles
(bottom panel) were analyzed for Gag-derived products by quantitative immunoblot (LiCor) using antiserum against HIV-1 CA. Positions of molecular
mass standards are shown to the left, Gag-derived processing products are indicated to the right. (C) Quantitative immunoblotting of cell lysates and
particles as shown in (B) was used to calculate the amount of released CA-containing proteins by quantification of band intensities using the LiCor
Odyssey 3.0 software. Relative release was calculated by dividing the sum of CA-reactive band intensities in the particle fraction by total CA-reactive
band intensities in cell lysates and particles. Mean values and SD from three independent experiments performed in duplicates are shown. p-values
were calculated using an unpaired student’s t-test (n.s. > 0.05, * < 0.05, *** < 0.001).






























































































Figure 3 Effect of p6 S40 substitutions on viral infectivity. Viral particles were harvested from cell culture media of HEK 293 T cells
transfected with proviral plasmids and tested for infectivity. Single round infectivity (A) was assessed by titration of viral particles on TZM-bl cells
as described in the main text. Relative infectious titers on C8166 T-cells (B) were determined by endpoint titration. Values were normalized to
p24 amounts determined by ELISA. Graphs show mean values and SD of one experiment using viral particles from six independent preparations.
p-values in (A) and (B) were calculated using an unpaired student’s t-test (n.s. > 0.05, * < 0.05, *** < 0.001).
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fected HEK 293 T cells. Virus replication was monitored
over two weeks by collecting culture supernatant every
second day and quantifying p24 release by ELISA. Replica-
tion of the late(-) (Figure 4A) and S40F variants (Figure 4B)
was completely abolished in PBMC, consistent with their
severe replication defect in established cell lines. The repli-
cation defect of the S40F mutant in PBMCs was even
more severe than in a previous report analyzing replica-
tion in primary human lymphocyte aggregate cultures,
where residual and delayed replication had been observed
[10]. Most importantly, however, replication kinetics of
the S40N, FL, and FL-N40S variants in PBMC were indis-
tinguishable from wild-type HIV-1NL4-3unc (Figure 4A, B),
demonstrating that the serine residue itself and phosphor-
ylation at this site are both dispensable for HIV-1 replica-
tion in primary T-cells.A

























Figure 4 Replication kinetics of HIV-1 variants in PBMC. PBMC were iso
three days using PHA and IL-2. Subsequently, cells from three individual do
293 T cells transfected with the respective proviral plasmids was added in
were collected at the indicated time points and virus production was mea
independent virus preparations are shown; data represent mean values and
late(-). (B) Replication kinetics of HIV-1NL4-3uncwt, S40N, and S40F.In summary, our analyses confirm previous reports
that an S40F substitution in p6Gag of HIV-1 impairs Gag
processing at the CA-SP1 site and severely affects or
abolishes HIV-1 replication in cell lines and primary
cells [9,10]. This effect is not due to either a requirement
for the conserved serine residue at this position or for
phosphorylation of S40. The conservative substitution of
S40 by a chemically similar, but not phosphorylatable
Asn residue had no effect on Gag processing or viral in-
fectivity in cell lines or primary T-cells compared to
wild-type HIV-1. Thus, the previously described replica-
tion defect of the S40F variant appears to be due to the
replacement of the small, hydrophilic serine by a bulky
hydrophobic phenylalanine residue, rather than indicat-
ing a requirement for S40. We did not analyze Gag
membrane-binding properties, which had been reported
to be affected by the S40F substitution or by introducingB
























lated using buffy coats from healthy blood donors and stimulated for
nors were mixed, and virus harvested from cell culture media of HEK
triplicates (0.1 ng p24 / 3 × 105cells). Samples of cell culture media
sured by p24 ELISA. Results from one infection experiment using six
SD. (A) Replication kinetics of HIV-1NL4-3uncwt, FL, FL-N40S, and NL4-3
Radestock et al. Retrovirology  (2014) 11:114 Page 5 of 5a phosphomimick in this position [11]. However, wild-
type release, polyprotein processing and infectivity of all
variants studied here except for S40F suggest that nei-
ther S40 nor its phosphorylation is needed for fully func-
tional membrane binding of Gag. Furthermore, we did
not observe a block in Vpr incorporation upon mutation
of S40, which had been reported for an S40A variant in
a previous study and had been proposed to result in im-
paired replication in primary macrophages [6]. While we
cannot exclude that S40 in p6Gag and/or its phosphoryl-
ation may be relevant in a different cell context (e.g.,
macrophages), we conclude that the phenotypes re-
ported in previously published studies [6,9-11] were
most likely caused by the specific mutation introduced
and do not reflect the functional importance of Ser40 or
its phosphorylation.
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